Novo's next-gen obesity drug shows positive results, heads to late-stage testing

Thread starter International: Top News And Analysis
Start date Nov 25, 2025

International: Top News And Analysis

Guest

Nov 25, 2025

Novo Nordisk said its experimental drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes.

Continue reading...

You must log in or register to reply here.

Facebook X Bluesky LinkedIn Reddit Pinterest Tumblr WhatsApp Email Link

Thread Information

Title: Novo's next-gen obesity drug shows positive results, heads to late-stage testing

Prefix: N/A

Forum: World News

Start date: Nov 25, 2025

Last reply date: Nov 25, 2025

Replies: 0

Thread Tags

Thread statistics

Created: International: Top News And Analysis, Nov 25, 2025

Replies: 0

Views: 9

About Us

XenTR Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Color picker

Search